Literature DB >> 32409773

The therapeutic potential of BRD4 in cardiovascular disease.

Shigang Lin1, Lizhong Du2.   

Abstract

Bromodomain-containing protein 4 (BRD4) is a member of the bromodomain and extra terminal (BET) protein family that has gained wide attention in the field of cancer due to its role in the formation of super enhancers (SEs) and the regulation of oncogene expression. However, there is increasing evidence that BRD4 also plays a pivotal role in a variety of cardiovascular diseases, suggesting that understanding the mechanisms of BRD4 in these diseases is important to advance studies and clinical treatment. In this article, we summarize the mechanisms of BRD4 in cardiovascular diseases, including pulmonary arterial hypertension, heart failure, atherosclerosis, and hypertension. In addition, we discuss small molecule inhibitors of BRD4 as novel therapeutic strategies for cardiovascular diseases.

Entities:  

Keywords:  Atherosclerosis; BRD4; Cardiovascular disease; Heart failure; Pulmonary arterial hypertension

Year:  2020        PMID： 32409773     DOI： 10.1038/s41440-020-0459-4

Source DB:  PubMed          Journal:  Hypertens Res        ISSN： 0916-9636            Impact factor:   3.872


  74 in total

Review 1.  Bromodomain: an acetyl-lysine binding domain.

Authors:  Lei Zeng; Ming Ming Zhou
Journal:  FEBS Lett       Date:  2002-02-20       Impact factor: 4.124

2.  Inflammation and salt sensitivity in the early state of hypertension.

Authors:  Tomohiro Katsuya; Hiromi Rakugi; Toshio Ogihara
Journal:  Hypertens Res       Date:  2007-02       Impact factor: 3.872

Review 3.  Statins in the primary prevention of cardiovascular disease.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2013-06-04       Impact factor: 32.419

Review 4.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition.

Authors:  Junwei Shi; Christopher R Vakoc
Journal:  Mol Cell       Date:  2014-06-05       Impact factor: 17.970

Review 5.  The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation.

Authors:  Shwu-Yuan Wu; Cheng-Ming Chiang
Journal:  J Biol Chem       Date:  2007-02-28       Impact factor: 5.157

6.  BET acetyl-lysine binding proteins control pathological cardiac hypertrophy.

Authors:  Jessica I Spiltoir; Matthew S Stratton; Maria A Cavasin; Kim Demos-Davies; Brian G Reid; Jun Qi; James E Bradner; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2013-08-09       Impact factor: 5.000

7.  Cooperative binding of two acetylation marks on a histone tail by a single bromodomain.

Authors:  Jeanne Morinière; Sophie Rousseaux; Ulrich Steuerwald; Montserrat Soler-López; Sandrine Curtet; Anne-Laure Vitte; Jérôme Govin; Jonathan Gaucher; Karin Sadoul; Darren J Hart; Jeroen Krijgsveld; Saadi Khochbin; Christoph W Müller; Carlo Petosa
Journal:  Nature       Date:  2009-10-01       Impact factor: 49.962

Review 8.  BRD4 and Cancer: going beyond transcriptional regulation.

Authors:  Benedetta Donati; Eugenia Lorenzini; Alessia Ciarrocchi
Journal:  Mol Cancer       Date:  2018-11-22       Impact factor: 27.401

9.  Thyrotropin aggravates atherosclerosis by promoting macrophage inflammation in plaques.

Authors:  Chongbo Yang; Ming Lu; Wenbin Chen; Zhao He; Xu Hou; Mei Feng; Hongjia Zhang; Tao Bo; Xiaoming Zhou; Yong Yu; Haiqing Zhang; Meng Zhao; Laicheng Wang; Chunxiao Yu; Ling Gao; Wenjian Jiang; Qunye Zhang; Jiajun Zhao
Journal:  J Exp Med       Date:  2019-04-02       Impact factor: 14.307

10.  Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4.

Authors:  Francesca Zanconato; Giusy Battilana; Mattia Forcato; Letizia Filippi; Luca Azzolin; Andrea Manfrin; Erika Quaranta; Daniele Di Biagio; Gianluca Sigismondo; Vincenza Guzzardo; Pascale Lejeune; Bernard Haendler; Jeroen Krijgsveld; Matteo Fassan; Silvio Bicciato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Nat Med       Date:  2018-09-17       Impact factor: 53.440
View more
  7 in total

Review 1.  Stem cell therapy for pulmonary arterial hypertension: An update.

Authors:  Qiwei Wilton Sun; Zhongjie Sun
Journal:  J Heart Lung Transplant       Date:  2022-03-06       Impact factor: 13.569

Review 2.  Beyond the marks: reader-effectors as drivers of epigenetics and chromatin engineering.

Authors:  Kierra A Franklin; Cara E Shields; Karmella A Haynes
Journal:  Trends Biochem Sci       Date:  2022-05       Impact factor: 14.264

3.  BRD4 Inhibition Suppresses Senescence and Apoptosis of Nucleus Pulposus Cells by Inducing Autophagy during Intervertebral Disc Degeneration: An In Vitro and In Vivo Study.

Authors:  Guang-Zhi Zhang; Hai-Wei Chen; Ya-Jun Deng; Ming-Qiang Liu; Zuo-Long Wu; Zhan-Jun Ma; Xue-Gang He; Yi-Cheng Gao; Xue-Wen Kang
Journal:  Oxid Med Cell Longev       Date:  2022-03-11       Impact factor: 6.543

Review 4.  Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review.

Authors:  Xiaona Chen; Yanhong He; Wenjun Fu; Amirhossein Sahebkar; Yuhui Tan; Suowen Xu; Hong Li
Journal:  Front Cell Dev Biol       Date:  2020-11-12

Review 5.  Targeting Epigenetics and Non-coding RNAs in Myocardial Infarction: From Mechanisms to Therapeutics.

Authors:  Jinhong Chen; Zhichao Liu; Li Ma; Shengwei Gao; Huanjie Fu; Can Wang; Anmin Lu; Baohe Wang; Xufang Gu
Journal:  Front Genet       Date:  2021-12-20       Impact factor: 4.599

Review 6.  Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor.

Authors:  Na Liu; Rui Ling; Xiang Tang; Yunpeng Yu; Yuepeng Zhou; Deyu Chen
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

Review 7.  Estrogen signaling as a bridge between the nucleus and mitochondria in cardiovascular diseases.

Authors:  Emanuel Guajardo-Correa; Juan Francisco Silva-Agüero; Ximena Calle; Mario Chiong; Mauricio Henríquez; Gerardo García-Rivas; Mauricio Latorre; Valentina Parra
Journal:  Front Cell Dev Biol       Date:  2022-09-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.